Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in diffuse cutaneous systemic sclerosis
jRCT2051200133Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of guselkumab in systemic sclerosis (SSc) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from Baseline in Modified Rodnan Skin Score (mRSS) at Week 24. Started Mar 2021; status: completed.
02
Drugs
guselkumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2051200133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051200133.